BioSpace News Archive

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II). The company plans to initiate a pivotal trial of

BioCardia®, Inc. [Nasdaq: BCDA] today announced that the Company’s proprietary Helix Biotherapeutic Delivery System (the Helix System) demonstrated the best safety profile among clinical transendocardial catheter injection systems used for cardiac cell therapy delivery in an in-press corrected proof published in the journal, Cardiovascular Revascularization Medicine

Completion of rolling submission for the BLA expected in 1H2 1 NDA for u mbralisib monotherapy currently under review with the FDA ; PDUFA goal date of February 15, 2021 for MZL and June 15, 2021 for FL

AMI Expeditionary Healthcare is contracted by Centers for Disease Control and Prevention to determine the prevalence of asymptomatic COVID-19 carriers on college campuses and what can be done to slow the spread of the disease.

CarepathRx, a leader in pharmacy and medication management solutions for vulnerable and chronically ill patients, announced a partnership with UPMC’s Chartwell subsidiary that will expand patient access to innovative specialty pharmacy and home infusion services.

- Expanded collaboration agreement with United Therapeutics which exercised its option for 3D bioprinted kidney transplants and $3 million payment to CollPlant - Increased revenues from 3D Bioprinting and Medical Aesthetics Business Collaborations

Stephen Mitchener Named Chief Business Officer, Bringing More than 17 Years of Partnering and Corporate Development Experience

Dr. Chen brings over twenty years of clinical research and development experience; including executing global registrational trials in relapsed and refractory AML

Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing totaling $62 million.

Change Healthcare and Carnegie Mellon University’s Delphi Research Group announced the launch of Delphi’s enhanced COVIDcast real-time COVID-19 indicators.